exemestane actavis 25 mg film-coated tablets
actavis group ptc ehf - exemestane - film-coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
exemestane 25mg film-coated tablets
accord healthcare ireland ltd. - exemestane - film-coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
exemestane 25 mg film-coated tablets
ltt pharma limited - exemestane - film-coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane
exemestane teva 25 mg film-coated tablets
teva b.v. - exemestane - film-coated tablet - aromatase inhibitors; exemestane
exemestane fair-med healthcare 25mg film-coated tablets
fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy
exedral 25, 25 mg film-coated tablets
remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy
exemestane 25mg film-coated tablets tablets film-coated
accord healthcare limited - exemestane - tablets film-coated - 25mg
exemestane sandoz
sandoz pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: mannitol; polysorbate 80; microcrystalline cellulose; hypromellose; macrogol 400; colloidal anhydrous silica; titanium dioxide; magnesium stearate; sodium starch glycollate type a; crospovidone - exemestane sandoz is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,exemestane sandoz is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.
exemestane
accord healthcare limited - exemestane - film coated tablet - 25 milligram - exemestane
exemestane gh exemestane 25mg tablet blister pack
generic health pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate type a; hypromellose; magnesium stearate; mannitol; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.